Targets › CEBPB
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.
Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. Also plays a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. (UniProt, P17676)
Open in Phaseline: the race on CEBPB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Xfibra | XFB19 C/EBPβ Thr266 phosphorylation inhibitor targeting NLRP3 inflammasome activation | CEBPB | Phase 1 | Focus of the Study: Safety of XFB19 | Dec 2026 |
Focus of the Study: Safety of XFB19 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.